Sermorelin is a synthetic 29-amino acid peptide that mimics the body's natural growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce and secrete growth hormone; it has been used clinically for diagnosing GH deficiency and is now common in anti-aging and body composition protocols.
What it does
Sermorelin is a truncated copy of endogenous GHRH — specifically its first 29 amino acids, which carry the full biological activity of the natural hormone. It binds to GHRH receptors (GHRHR) on pituitary somatotrophs (the cells that make and release growth hormone), triggering a chain reaction: the enzyme adenylyl cyclase is activated, cyclic AMP (cAMP) rises, and protein kinase A (PKA) is switched on, which drives transcription of the GH gene and release of GH into circulation. The pathway is identical to that used by CJC-1295 Mateo 2023.
The key practical difference between sermorelin and CJC-1295 is half-life. Sermorelin carries no modifications to resist DPP-IV, an enzyme that rapidly chops up GHRH-like peptides. Its half-life is roughly 10–20 minutes, meaning it produces a short, sharp GH pulse rather than the prolonged elevation seen with longer-acting analogs Mateo 2023. Because GH is naturally released in pulses — especially during deep sleep — pre-bedtime dosing is designed to amplify one of those natural peaks rather than create a sustained artificial elevation Ebru 2026.
Sermorelin was the first FDA-approved GH secretagogue, cleared both as a diagnostic agent (Geref Diagnostic) to test pituitary GH axis function and as a treatment for pediatric GH deficiency. It was voluntarily withdrawn from the market for commercial, not safety, reasons, and remains available through compounding pharmacies.
What the evidence shows
Pediatric growth hormone deficiency Moderate human evidence — supported FDA approval, but older trial designs by current standards
Sermorelin's FDA approval for pediatric GH deficiency rested on clinical trials showing it could stimulate pituitary GH output and support linear growth in GH-deficient children. This is its best-documented use case in humans. The approval covered both diagnostic testing of the GH axis and therapeutic use, distinguishing it from most peptides in this class, which lack any regulatory approval Ebru 2026.
Adult body composition and anti-aging Weak direct human evidence for sermorelin specifically; extrapolated from GHRH analog class data
Sermorelin is widely used in compounding pharmacy anti-aging protocols, with the goal of raising IGF-1 (insulin-like growth factor 1, the downstream marker of GH activity), improving lean mass, reducing fat, and supporting sleep quality. Direct randomized controlled trial data for sermorelin in healthy adults is sparse. Most of the supporting evidence comes from studies on related GHRH analogs — including tesamorelin, which has solid human trial data for visceral fat reduction in HIV-associated lipodystrophy NCT06554717 — and the reasonable inference that sermorelin shares the same receptor and pathway Mateo 2023. Self-reported outcomes from compounding pharmacy users are broadly positive but uncontrolled.
GH axis diagnostic testing Strong — was the clinical standard; validated in human use
As Geref Diagnostic, sermorelin was used to distinguish hypothalamic from pituitary causes of GH deficiency. An absent or blunted GH response to sermorelin injection pointed toward pituitary failure; a normal response suggested the deficit lay upstream. This diagnostic use is well-validated and was the application with the clearest mechanistic and clinical rationale Ebru 2026.
How it's used
In studies and self-reported compounding pharmacy protocols, doses range from 100 mcg to 500 mcg administered subcutaneously (injected into fat under the skin). The most commonly reported range is 200–300 mcg per evening. Timing is consistently pre-bedtime — ideally 30 or more minutes away from food — to align the induced GH pulse with natural nocturnal GH secretion. Because sermorelin's half-life is only 10–20 minutes Mateo 2023, once-daily dosing is the norm; splitting doses provides diminishing returns given the rapid degradation. Obese individuals tend to have a blunted pituitary GH response to GHRH stimulation, which may reduce sermorelin's effectiveness at standard doses.
Side effects and safety
Reported side effects in clinical and self-report contexts are mostly mild: flushing, injection-site reactions (redness, discomfort), and brief dizziness. Moderate effects include headache, nausea, and drowsiness — consistent with a short, sharp GH pulse. The drowsiness is sometimes considered a feature when dosing pre-sleep. The most significant safety concern is theoretical tumor growth acceleration: GH and IGF-1 are mitogenic (they promote cell growth and division), so active malignancy is an absolute contraindication. GHRH receptor signaling has been studied extensively in the context of cancer biology, and GHRH antagonists — the functional opposite of sermorelin — are under active investigation as anti-cancer agents Madan 2025 Iacopo 2025 Laura 2024 Joel 2025. This research does not prove sermorelin causes cancer, but it underscores why anyone with an active or recent malignancy should not use it. Diabetes and thyroid disease warrant monitoring, as GH affects insulin sensitivity and thyroid hormone interactions. Long-term safety data in healthy adults is essentially absent — this is an important gap, not a minor caveat.
Bottom line
Sermorelin has the strongest regulatory history of any GHRH analog — genuine FDA approval and a validated mechanism — but its ultra-short half-life makes it less practical than newer analogs like CJC-1295, and direct human efficacy data in adult anti-aging contexts is thin. It's a reasonable choice for someone who wants a GHRH analog with a long safety track record and access through a compounding physician, but anyone expecting robust clinical trial support for body composition benefits will be working largely on extrapolation.